The more potent disease-modifying drugs in multiple sclerosis are superior to low-efficacy therapy in reducing relapses in patients with active but not inactive secondary progressive multiple sclerosis (SPMS), Australian research shows. A study led by neurologists Dr Izanne Roos and Professor Tomas Kalincik, of the Clinical Outcomes Research (CORe) Unit, Melbourne University, investigated relapse rates ...
High-efficacy therapies reduce relapses in patients with active SPMS
By Michael Woodhead
1 Jul 2021